Open Nav

Imara Inc.,

  • Rahul Ballal, Imara

Setting up Series B Financning

  • Date:Wednesday, October 17
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:mara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease.
  • Company
  • Company HQ City:Cambridge
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • CEO/Top Company Official:Rahul Ballal
  • Year Founded:2016
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development :IMR-687
  • Development Phase of Primary Product:Phase II
  • Previous and Current Investors:NEA, Pfizer Investments, Lundbeck, Bay City Capital, ARE
  • Size of Last Investment Round:31MM
  • Total Amount Raised to Date, In All Rounds:31MM
Rahul Ballal